Antidepressant use, age, health linked to abnormal binocular vision

Article

According to research from the University of Waterloo in Canada, abnormal binocular vision dramatically increases with age, but is correlated with a patient’s general health and antidepressant use.

Waterloo, Canada-According to research from the University of Waterloo in Canada, abnormal binocular vision dramatically increases with age, but is correlated with a patient’s general health and antidepressant use. 

The study looked at records from 500 patients, ages 60 and over, who received treatment at the university’s on-campus clinic. Data included age, general and ocular history and symptoms, antidepressant use, smoking habits, refraction, visual acuity, binocular vision and eye movement status for the most recent full oculo-visual assessment, and an assessment from 10 years prior.

The study found that about 27 percent of adults in their 60s have a binocular vision or eye movement disorder, and that number rises to 38 percent for those over age 80. Age and use of antidepressants most commonly predicted binocular vision or eye movement disorders. In addition, about 20 percent of the general population has a binocular vision disorder.

According to the university, “Conditions such as diabetes and thyroid disease are known to cause such problems, but this is the first study to link binocular vision disorders with overall general health. Similarly, other writers have discussed a possible association between certain antidepressant drugs and specific binocular vision disorders, but this is the first study to actually demonstrate a link between antidepressant use and binocular vision and eye movement disorders.

"An association does not establish that one causes the other, but rather that they co-exist," says Susan Leat, BSc, PhD, FAAO, PCOptom, who led the study. "It is possible that the effects of poor vision mean that people are more likely to take anti-depressants or make less healthy lifestyle choices."

Next: Glaucoma drug may reverse obesity-related vision loss

Tracrolimus drops associated with improvement of refractory allergic ocular disease

Recent Videos
John Berdahl, MD, overviews the new FYXS Ocular Pressure Adjusting Pump and HERCULES trial at the Glaucoma 360 meeting.
Although 2025 is predicted to remain stable, the forecast for the optical industry still remains uncertain.
Ashley Wallace Tucker, OD, FAAO, FSLS, Dipl ABO, weighs in on what's on the horizon for pediatric myopia management, and provides some tips for diving into scleral lens fitting.
Prominent legislation includes the Corporate Transparency Act and last year's spending bill provision that was struck down.
Shan Lin, MD, outlines a new generation of minimally invasive glaucoma surgeries (MIGS) at Glaucoma 360.
Steven T. Reed, OD, talks Optometry's Meeting and public-facing initiatives that optometrists can take advantage of.
For Ashley Wallace Tucker, OD, FAAO, FSLS, Dipl ABO, last week's conference gives a unique opportunity for optometrists and ophthalmologists to collaborate.
Steven T. Reed, OD, American Optometric Association's president, overviews the 2024 highlights and how the organization plans to extend success into 2025.
Ashley Mills, The Vision Council CEO, outlines new additions to the show that are unveiling what is to come in terms of fashion, technology, and patient care.
© 2025 MJH Life Sciences

All rights reserved.